Join Windtree Therapeutics for a virtual investor day featuring the new positive topline results of the Phase 2b SEISMiC Extension Study of istaroxime in early cardiogenic shock, istaroxime cardiogenic shock opportunity and the Windtree’s strategy going forward, including planned near-term milestones.

Alexandre Mebazaa MD, PhD, FESC (Université Paris Cité, France), a top cardiology expert, will discuss the unmet need and current treatment landscape for patients with cardiogenic shock caused by heart failure.

A live question and answer session will follow the formal presentations.